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Role of Tissue Exposure and DNA
Lesions for Organ Specific Effects of
Carcinogenic trans 4oAcetylaminostilbene
in Rats
by Hans-Gunter Neumann*
trans-4-Acetylaminostilbene is acutely toxic to the glandular stomach and produces sebaceous
gland tumors in rats quite specifically. Metabolism, tissue exposure to reactive metabolites, DNA
binding and persistence of DNA lesions are implicated in tissue susceptibility, but nothing indicates
that one of these parameters determines the biological effect. All tissues are exposed to reactive me-
tabolites, liver as a nontarget tissue ranking highest. DNA binding in this tissue, however, is not ir-
relevant to tumor formation, but rather indicates the presence of initiating lesions. They can be
amplified by partial hepatectomy and/or promoters, such as phenobarbital, DDT and diethylstilbes-
trol. Liver tumors are formed in high yields with these treatments, and mammary tumors also
occur. trans-4-Acetylaminostilbene is therefore considered to be an incomplete carcinogen in these
tissues and may initiate cells in other tissues as well. Apparently it lacks promoting properties
which are supposed to be unrelated to reactive metabolites. It is concluded that DNA lesions do not
reflect tissue risk, but rather secondary effects ultimately determine where the process of tumor for-
mation starts and how fast it develops.
Introduction
An adequately performed animal experiment is
still necessary to distinguish carcinogenic from non-
carcinogenic chemicals. The recognition of carcino-
gens is straightforward if tumors arise in high
yields and in tissues not forming tumors spontan-
eously in the species under test. A borderline activ-
ity is much more difficult to interpret, and species,
strain and tissue-specific effects impede easy ex-
trapolation to the human situation. A better under-
standing of the underlying mechanisms is therefore
demanded.
Since the pioneering work of the Millers and
their associates (1), it is widely accepted that aro-
matic amines have to be metabolically activated and
that the reaction of metabolites with DNA produces
a decisive lesion which initiates the process of tu-
mor formation. Accordingly, attempts have been
made to correlate the extent of DNA lesions with
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the biological effect and to explain species, strain
and tissue susceptibility by differences in exposure
of the responsive tissue to reactive metabolites, due
to specific balances between activating and inacti-
vating metabolism. This concept had to be extended
when the modulating properties of repair processes
were detected. However, even if persistence of the
DNA lesion is included in the considerations, it is
difficult to find satisfactory correlations. From our
studies with aminostilbene derivatives, which are
carcinogenic and produce tumors quite selectively
in sebaceous glands of rats, we conclude that sub-
stance-related effects not involving metabolic activa-
tion as well as tissue specific parameters contribute
and may ultimately determine the biological effect
(2, 3). Tissue-specific proliferation rates and their
modulation and factors which influence processes
collectively called promotion, including hormonal
control, are such secondary parameters. These as-
pects have been widely neglected in cell-free and
cell culture system investigations of the mechanism
of metabolic activation. Recent results from studies
of the fate of aminostilbene derivatives in rats will
therefore be described to illustrate some of the
problems involved in whole animal experiments and5H.-G. NEUMANN
to support the proposed role of secondary factors in
tumor formation.
Tissue Exposure and Primary
Lesion
It is difficult to follow the concentration of indi-
vidual metabolites in specific tissues with time in
the intact animal. Usually metabolites are isolated
and identified in urine, bile or sometimes blood, but
reactive intermediates are not readily obtained
from these sources. In tissues, the final reaction
products with cellular macromolecules are therefore
considered to indicate their presence. Covalent
binding to proteins may be used to approximate
tissue exposure. Although protein adducts may not
reflect the exact pattern of metabolites reacting
with nucleic acids, they may be formed by common
metabolic precursors or even the same ultimate re-
active metabolites. We have tentatively identified
one of the protein adducts as a sulfinic acid amide
which results from the reaction of trans4-nitroso-
stilbene with the SH-group of cysteine (4). The ad-
duct can be analyzed by mild acidic hydrolysis
which releases trans4-aminostilbene (Fig. 1). It con-
stitutes 70% of the adducts in hemoglobin and it is
also present in plasma and tissue proteins to a
smaller extent (5). This indicates the presence not
only of trans4-nitrosostilbene but also of trans-4-N-
hydroxylaminostilbene in blood and tissue. Both
compounds are direct mutagens and therefore have
genotoxic potential. Methylmercapto derivatives of
trans4-acetylaminostilbene (trans-AAS) have also
been identified after acidic hydrolysis of tissue
proteins (5), which indicates the reaction of methio-
nine with a hydroxamic acid ester, which is also
potentially genotoxic.
Three days after administration of radiolabeled
trans-AAS to rats, protein-bound metabolites are
found in all tissues, and protein binding roughly par-
allels total radioactivity in a given tissue at that
time (Table 1). This allows approximation of tissue
exposure even in tissues from which macromole-
cules have not been isolated. According to these cri-
teria, all tissues measured are exposed to reactive
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FIGURE 1. Protein adducts with aryl nitroso compounds.
trans-4-Nitrosostilbene is a metabolite of trans AAS and
reacts with HS-groups of cysteine (4). Part of the primary
intermediate may be further reduced, another part
rearranges and forms a stable sulfinic acid amide which
may be hydrolyzed under mild acidic conditions.
metabolites, and exposure appears to vary only by a
factor of 10, with liver and kidney ranking highest,
and with lung, Zymbal's gland, glandular stomach
and mammary tissue following in decreasing order
(Table 1). The ratio between protein and DNA bind-
ing appears not to be constant in different tissues.
This may be explained by different turnover and se-
cretion of proteins and by different inactivation of
reactive metabolites on their course from the cyto-
sol to the cell nucleus. In the experiment described,
the ratio varied from 18:1 in lung to 1:1 in forestom-
ach (data not shown) 3 days after dosing. Tissue ex-
posure and exposure of DNA are therefore not iden-
tical, and we prefer to describe the latter as the pri-
mary lesion. Even on this level however, all tissues
are found to be affected, and the extent of the lesion
does not permit discrimination between susceptible
and nonsusceptible tissues.
Table 1. Exposure and DNA binding in different rat tissues.a
Zymbal's Glandular Mammary
Liver Kidney Lung gland stomach gland
Total radioactivity, pmole/mg wet weight 2.4 1.8 0.7 0.4 0.3 0.2
Protein binding, pmole/mg 6.6 2.0 1.4 N.D. 0.7 N.D.
DNA binding, pmole/mg 5.2 0.7 0.1 N.D. 0.6 N.D.
a(3H)-trans-AAS (5gmole/kg) was orally administered to female Wistar rats. After 3 days, total radioactivity, protein-bound and
DNA-bound radioactivities were determined in various tissues (x, n = 3; standard deviation <25%).
N.D. = not determined.
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Modulation of Tissue Exposure
by Metabolism
Tissue-specific effects are often thought to be
caused by tissue-specific metabolic activation. Total
binding to proteins and nucleic acids does not ac-
count for the possible presence of particularly criti-
cal metabolites. Therefore, the metabolic pathways,
distribution and sites of formation for reactive me-
tabolites must be determined. Studying the metabo-
lism of acute toxic doses of trans-AAS, we have now
obtained additional data which support our conclu-
sion that liver metabolism largely determines expo-
sure of extrahepatic tissues (6). Acute toxic doses of
trans-AAS quite specifically damage the prolifer-
ating isthmus cells in the antrum of the glandular
stomach and the blood cell-forming bone marrow (7).
Since these effects can be suppressed by pretreat-
ment with methylcholanthrene (MC), but not with
phenobarbital (PB), this indicates a role of metabolic
activation (Table 2). The consequences of MC pre-
treatment were therefore studied on the level of
metabolism, tissue exposure and DNA binding.
Phase I and phase II metabolism are altered consi-
derably (Tables 3 and 4). The conjugation pattern in
urine and bile indicates that the conjugation capac-
ity is increased by the protecting pretreatment.
Binding to blood proteins, particularly hemoglobin,
is lowered, which indicates that less N-oxidized, i.e.,
activated, metabolites are distributed by the blood
Table 2. Acute toxicity of trans-AAS.a
Dose, Lethal Latency, Weight
Treatment mg/kg effects days loss, %
trans-AAS 50 5/6b 12 40
(propanediol)
trans-AAS 75 6/6 13 15
(tricaprylin/30% DMSO)
MC + trans-AAS 75 0/6c 10
atrans-AAS was administered by gavage to female Wistar
rats.
bOne animal developed a mammary tumor after 30 weeks.
'Five animals developed tumors within 1 year.
stream (Table 5). As a consequence, all extrahepatic
tissues are less exposed (Table 6). In the toxic situ-
ation, the glandular stomach as a target tissue is ex-
posed to the same extent as other extrahepatic tis-
sues, and the protective pretreatment lowers expo-
sure and DNA damage in all tissues. It is therefore
unlikely that metabolic activation specific to this tis-
sue causes toxicity and that tissue-specific inactiva-
tion provides protection. This is in accordance with
previous experiments with nontoxic doses, in which
a similar pattern of DNA adducts revealed that all
four of the above studied tissues are exposed to the
same reactive metabolites (10). However, this may
not hold true if the carcinogen is administered
chronically, because drug-metabolizing enzymes in
liver or extrahepatic tissues may be induced. How-
ever, this confounding effect can be excluded be-
Table 3. Excretion of trans-AAS metabolites in urinea.
Metabolites, nmole
Pretreatment AAS 4'-OH-AAS 4'-OH-AS 3-OH-AAS erythrodiol threodiol
Without MC 50 200 32 183 770 320
With MC 29 46 9 104 185 39
a(3H)-trans-AAS (210 Amole/kg) was administered orally to female Wistar rats and urine was collected for 24 hr. Conjugates were
separated by chromatography on alumina (cf. Table 4), unconjugated metabolites, sulfates and glucuronides were analyzed by
HPLC separately after hydrolysis (Pfeifer and Neumann, unpublished), and the metabolites contained in these three fractions
added. AS 4-aminostilbene, diol = 4-acetylaminobibenzyl-a,4-diol. Animals pretreated with MC excreted larger amounts of
unidentified metabolites than untreated animals. (x, n = 2).
Table 4. Metabolite pattern in urine and bile after toxic trans-AAS doses.a.
Metabolites, %
Urine Bile
No MC No MC
pretreatment pretreatment pretreatment pretreatment
Unconjugated metabolites 39.4 19.3 3.2 2.7
Sulfates 23.1 42.2 25.1 2.9
Glucuronides 12.0 18.8 21.1 25.6
Polar metabolites 24.5 16.7 46.5 65.6
(Mercapturic acids)
a(3H)-trans-AAS (210 ,umole/kg) was administered orally to female Wistar rats with and without MC pretreatment (3 x 20 mg/kg).
Metabolites in urine (24 hr) and bile (12 hr) were analyzed by chromatography on alumina (8); (x, n = 2, deviation <25%).
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cause when 12 doses were administered within 6
weeks, tissue exposure remained constant for each
dose, and DNA damage accumulated (Table 7).
Repair
Although accumulation of DNA damage in the
previous experiment already precluded tissue-
specific repair of the initial lesions as a gross modu-
lating factor, we measured the elimination rate of
DNA-bound metabolites at different times during
the course of administration and found it to remain
constant up to the 12th dose (Table 7). Repair pro-
cesses are therefore neither induced nor inhibited
with this protocol.
Table 5. Covalent binding to blood proteinsa.
Protein binding, pmole/mg
Pretreatment Plasma proteins Hemoglobin
Without MC 151 + 10 674 + 136
With MC (3 x 20 mg/kg) 57 ± 8 29 ± 9
a(3H)-trans-AAS (210 Amole/kg) was administered orally to
female Wistar rats with and without MC pretreatment. Blood
was obtained after 24 hr, and proteins were processed (9); (x, n
= 2).
Initiation-Promotion
At this point, the question had to be answered
whether or not the persistent and accumulating
DNA damage could be regarded at all as indicating
an initial lesion in terms of tumor initiation. The
possibility had to be ruled out that the total binding
measured with DNA obtained from whole tissue ho-
mogenates is entirely irrelevant with respect to tu-
mor formation. Actually one should expect only that
some, as yet undefined, critical lesion, which consti-
tutes only a small fraction of total binding, would
correlate with biological effects. However, pharma-
cokinetic considerations make it quite likely that a
certain correlation also exists between a critical
lesion and the total DNA lesion. As long as the criti-
cal event cannot be defined, this correlation cannot
be determined. It should be possible, however, to
demonstrate whether or not there is a critical lesion
at all among the persistent DNA-lesions, if sec-
ondary effects can be found which amplify the pri-
mary effect. For liver, partial hepatectomy is known
to increase cell proliferation and therefore to im-
prove fixation of an initial lesion (11, 12). In addition,
promoters like PB and DDT may enhance the
growth of intiated cells (13-15). We have therefore
Table 6. Exposure and DNA binding in different rat tissuesa.
Protein/binding, pmole/mg DNA/binding, pmole/mg
No MC No MC
Tissue pretreatment pretreatment pretreatment pretreatment
Liver 219 329 80 50
Kidney 52 36 20 5
Lung 72 9 3 2
Glandular stomach 60 9 15 5
a(3H)-trans-AAS (210 .mole/kg) was administered orally to female Wistar rats with and without MC pretreatment (3 x 20
mg/kg). After 24 hr, proteins and DNA were isolated from different tissues (10); (x, n = 2, deviation <17%).
Table 7. Accumulation and elimination of DNA-bound metabolitesa.
Accumulation, pmole/mg, Elimination of DNA-bound metabolites,
3 days after 12 doses t,,2 between day 3 and 17 after dosing, days
Tissue Total tissue DNA binding 1 dose 4 doses 8 doses 12 doses Average
Liver 7.2 24.4 23 38 17 11 22
Kidney 7.0 17.1 persistent
Lung 3.0 1.9 15 26 16 15 18
Zymbal's gland 1.4 N.D. N.D.
Glandular stomach 1.3 3.9 10 7 10 10 9
Mammary tissue 0.8 N.D. N.D.
aThe results of two different experiments are summarized: (1) to determine accumulation, 12 (3H)-trans-AAS doses (5gmole/kg,
twice weekly) were orally administered and total radioactivity as well as DNA binding were measured 3 days after the last dose.
(x, n = 3, standard deviation <25%); (2) to determine the elimination rate during the administration period, only one labeled dose
was administered after various unlabeled trans-AAS doses, and DNA binding was measured 3 and 17 days after the last dose (x, n
= 2).
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performed an initiation-promotion experiment and
included diethylstilbestrol (DES) to test the promot-
ing properties of estrogenic hormones in liver (16,
17). The protocol is shown in Figure 2 and the re-
sults are shown in Table 8.
The trans-AAS dose turned out to be moderately
carcinogenic, producing sebaceous gland tumors in
half the animals within one year. Up to this time,
neither enzyme-deficient foci nor hyperplastic nod-
ules could be detected in the liver. If trans-AAS ad-
ministration was followed by partial hepatectomy,
preneoplastic lesions as well as hepatomas were ob-
served. Feeding DDT and DES alone to pretreated
animals produced similar effects. Tumor formation
was particularly increased and the latent period
shortened if partial hepatectomy and promoter
feeding were combined.
These results clearly demonstrate that trans-
AAS induces critical lesions in liver. In addition, tu-
mors grew in mammary tissue, a tissue which had
been shown to be exposed the least (Table 1). DES
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was particularly effective in promoting these tu-
mors. This observation indicates a trans-AAS-re-
lated effect, since mammary tumors were not ob-
served in any one of the control groups up to that
time.
Several questions may be asked at this point: (1)
does partial hepatectomy induce only the fixation of
DNA damage? If this were the case, fixation would
be sufficient to start the whole process; alterna-
tively, does this procedure exert an additional pro-
moting activity? (2) Are promoters able to fix an
initial lesion like partial hepatectomy (for instance
by stimulating cell proliferation), or is fixation in the
sense of a mutational mechanism unneccesary to
amplify the initial lesion?
Biochemical Effects of Partial
Hepatectomy and Promoters
The stimulating effect of partial hepatectomy on
cell proliferation can be directly demonstrated by
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FIGURE 2. Protocol of the initiation-promotion experiment. After 24 and 46 weeks, two animals of each group were sacrificed, and
livers were histologically examined for enzyme-deficient foci (alkaline phosphatase), increased glycogen storage and hyper-
plastic nodules. Solv = solvent; PH = partial hepatectomy.
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Table 8. Effects of partial hepatectomy and promoters on tumor incidence after trans-AASa.
Tumor localization
Sebaceous glands Liver
Zymbal's Hyperplastic Mammary
Treatment n Incidence gland Lip nodule Hepatoma Cholangioma tissue
Solvent 10 0/10 - - - - - -
Solvent + PH + PB 8 0/8 - -
AAS 9 4/9 3 2 - - - -
AAS + PH 10 8/9 1 - 6 2 - 2
AAS + PH + PB 12 11/11 3 2 4 7 1 -
AAS + DDT 10 6/6 1 - 2 4 2 1
AAS + PH + DDT 14 11/13 2 - 3 7 - 1
DES 10 0/10 - - - - - -
AAS + DES 10 9/10 1 2 4 5 1 5
AAS + PH + DES 14 12/12 1 - 6 6 2 1
aThe experiment was terminated after 54 weeks, except for the control groups. Tumors were histologically verified. Hyper-
plastic nodules are contained in the incidence rate. It was not attempted to specify the malignancy of liver tumors.
Table 9. Effects of partial hepatectomy (PH) on DNA binding.a
DNA binding, pmole/mg
Liver Kidney Lung Glandularstomach
Treatment 1 day 17 days 1 day 17 days 1 day 17 days 1 day 17 days
AAS 7.8 2.9 0.7 0.7 0.25 0.10 0.5 0.18
PH 24 hr before AAS 5.8 0.6*** 1.6*** 1.4** 0.64** 0.40*** 1.1** 0.45***
PH 24 hr after AAS 3.5 0.7*** 0.9 0.8 0.30 0.16* 0.5 0.34***
a(3H)-trans-AAS (51.mole/kg) was administered orally to female Wistar rats. Either 24 hr before or 24 hr after dosing a two-thirds
hepatectomy was performed and DNA binding was determined either 1 or 17 days after dosing (x, n = 3). The significance of
differences to the control values is indicated.
*p<0.1.
**p<0.05.
***p<0.001.
the more rapid reduction of DNA-bound metabolites
compared to untreated controls. DNA synthesis di-
lutes specific binding, particularly during the first
days after partial hepatectomy. Binding is reduced
to 20% of that of the controls after 17 days (Table
9). The initial DNA binding is similar, regardless of
whether or not partial hepatectomy is performed
before or after dosing. This means that rapidly pro-
liferating liver cells metabolize the carcinogen at
the same rate as normal cells; in terms of DNA
binding, this means that liver cells are not preferen-
tially affected unless the two effects cancel each
other out.
Promotors do not stimulate liver cell proliferation
nearly as much, if at all, as partial hepatectomy.
Correspondingly, specific DNA binding of trans-
AAS-metabolites does not decrease in liver. With
DDT it even increases somewhat (Table 10). It is
therefore unlikely that promoters contribute to fixa-
tion of DNA damage to an extent comparable to
that of partial hepatectomy. These findings would
support the notion that a specific lesion is amplified
by partial hepatectomy directly, i.e., through DNA
synthesis, and by promoters indirectly through
stimulating the expression of altered cell properties.
An irreversible change would be a prerequisite for
both mechanisms.
The last two experiments demonstrate, in addi-
tion, that the applied procedures do not only affect
the liver. A preceding partial hepatectomy in-
creases DNA binding in all extrahepatic tissues
(Table 9, in this situation extrahepatic metabolism
contributes significantly), and decreases the elimina-
tion between day 3 and 17 (data not shown) of DNA-
bound metabolites in glandular stomach and lung.
The latter effect is also observed with subsequent
partial hepatectomy and is more pronounced in lung
than in glandular stomach and kidney. After 2
weeks of promoter feeding, specific DNA binding is
greater in experimental than in control animals in
all tissues studied. In kidney, even an absolute in-
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Table 10. Effects of promoters on DNA binding.a
DNA binding, pmole/mg
Liver Kidney Lung Glandular stomach
Treatment 3 days 17 days 3 days 17 days 3 days 17 days 3 days 17 days
AAS 4.5 2.9 0.9 0.7 0.28 0.10 0.38 0.18
AAS + PB 5.5* 2.7 1.0 1.5** 0.22 0.15* 0.35 0.25**
AAS + DDT 5.9** 3.8* 1.1 1.9*** 0.20 0.22** 0.38 0.30**
AAS + DES 4.5 2.3 1.3 2.7**** 0.35 0.15* 0.58 0.28**
a(3H)-trans-AAS (5Mmole/kg) was administered orally to female Wistar rats. Promoters were added to the feed from the next day
at the following concentrations: PB, 500 ppm; DDT, 500 ppm, DES, 10 ppm. DNA binding was determined in different tissues 3 and
17 days after dosing (x, n = 3). Values were significantly different from the controls as indicated.
*p<0.1.
**p<0.05.
***p<0.001.
crease is observed; this is largest with DES (Table
10).
Conclusions
According to the definition outlined in the intro-
duction, trans-AAS is a strong and complete carcin-
ogen. This statement may now be modified: trans-
AAS is a complete carcinogen for sebaceous glands,
but an incomplete carcinogen for liver and mam-
mary tissue, and it may be an incomplete carcino-
gen for other tissues as well. Since the extent of ac-
cumulating and persistent DNA damage, which ap-
parently indicates the presence of initiating DNA le-
sions, does not correlate with the biological effects,
it has to be postulated that secondary effects modu-
late the primary lesion and may ultimately deter-
mine where the process of tumor formation starts
and how fast it develops. The proliferation rate and
endogenous hormonal stimulation may be decisive
in Zymbal's gland. In mammary tissue, an exoge-
nous hormonal stimulus (or inhibition of prolactin in-
hibiting factor) was most effective. This raises the
question, what does trans-AAS lack to make it a
complete carcinogen for liver? Obviously, the pro-
moting properties, rather than the initiating, are ab-
sent. 2-Fluorenylacetamide has been shown to pos-
sess both properties. It induces drug metabolizing
enzymes (18-20) and thus shares a trait common to
other typical promoters, and it is also toxic to liver
tissue. Trans-AAS, in contrast, neither induces en-
zymes (21) nor is toxic to liver, even in lethal doses
(7).
Other examples of incomplete liver carcinogens
have been described recently. 2-Methyl-4-dimethyl-
aminoazobenzene (22, 23) was classified noncarcino-
genic but induced tumors after additional promo-
tion. Benzo(a)pyrene (24) is a complete carcinogen
for many tissues after local administration, but pro-
duces liver tumors only with partial hepatectomy
and promotion. N-Acetylaminobiphenyl (25), a
known carcinogen for mammary tissue in rats, has
also been shown to initiate liver cells. It will there-
fore be necessary to include the multistage charac-
teristics of carcinogenesis (26) in risk evaluations
and to consider both genotoxic and epigenetic prop-
erties to assess the carcinogenic potential more pre-
cisely. The results described indicate that epige-
netic effects may be unrelated to reactive metabo-
lites, since trans-AAS metabolites react with DNA
and proteins to the same extent as hepatotoxic and
hepatocarcinogenic aromatic amines.
The unpublished data were taken primarily from the work
of Dietmar Hilpert and Andrea Pfeifer carried out in this
laboratory. The work was supported by the Deutsche
Forschungsgemeinschaft. We are also indebted for support by
R. J. Reynolds Tobacco GmbH and the Doktor Robert Pfleger
Stiftung, Bamberg.
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